Stockscreener 앱 받기
68.36
0.22%
-0.2566
전일 마감가:
$68.62
열려 있는:
$68.57
하루 거래량:
191.57K
Relative Volume:
0.20
시가총액:
$3.95B
수익:
$76.81M
순이익/손실:
$-162.42M
주가수익비율:
-22.86
EPS:
-2.99
순현금흐름:
$-122.49M
1주 성능:
-0.68%
1개월 성능:
+4.52%
6개월 성능:
-2.14%
1년 성능:
+4.71%
1일 변동 폭
$67.08
$69.14
1주일 범위
$66.00
$76.50
52주 변동 폭
$47.86
$94.07
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.38 | 3.97B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.02 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.49 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.79 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-22 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx to present anito-cel data at 2026 Tandem Meetings By Investing.com - Investing.com Nigeria
Arcellx to present anito-cel data at 2026 Tandem Meetings - Investing.com
Arcellx study: earlier CAR T cut 5-year death risk by 48% - Stock Titan
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Arcellx Stock Is Sliding Despite Future Hopes - TipRanks
Arcellx director Lubner sells $450k in ACLX stock - Investing.com
Why (ACLX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Legend Biotech, Arcellx rise after FDA draft guidance on multiple myeloma trials - MSN
FDA Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Shares - GuruFocus
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials - Seeking Alpha
Arcellx Stock Gains Momentum with New Buy Ratings - timothysykes.com
This Insider Has Just Sold Shares In Arcellx - simplywall.st
Assessing Arcellx (ACLX) Valuation After Strong Myeloma Data And Fresh Analyst Optimism - Sahm
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock By Investing.com - Investing.com India
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock - Investing.com
Positioning Arcellx for a Pivotal 2026: Anito-cel’s Differentiated Safety, Best-in-Class CAR T Launch Potential, and Undervalued Entry Point - TipRanks
Arcellx CMO Heery sells $487k in shares By Investing.com - Investing.com UK
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock - MarketBeat
Arcellx CMO Heery sells $487k in shares - Investing.com
Arcellx, Inc. Reports Increased Loss Amid Rising Expenses - MSN
Arcellx (ACLX) CMO Heery sells $393k in shares By Investing.com - Investing.com Australia
Christopher Heery Sells 6,131 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
How Investors May Respond To Arcellx (ACLX) ESOP Shelf Filing And Upbeat Kite Collaboration Coverage - simplywall.st
Understanding Momentum Shifts in (ACLX) - Stock Traders Daily
What technical signals suggest for Arcellx Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Pharma News: Is Arcellx Inc. stock vulnerable to regulatory risksWeekly Market Summary & AI Forecasted Stock Moves - Улправда
Why Arcellx Inc. stock could benefit from AI revolution2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - Улправда
ACLX: UBS Reaffirms Buy Rating Amid Stable Price Targets | ACLX Stock News - GuruFocus
Why Arcellx Stock Is Suddenly Catching Wall Street’s Eye - TipRanks
UBS initiates Arcellx stock coverage with Buy rating, $100 price target - Investing.com Nigeria
UBS initiates Arcellx stock coverage with Buy rating, $100 price target By Investing.com - Investing.com South Africa
Arcellx shares jump on strong multiple myeloma trial results - MSN
Arcellx, Inc. (ACLX) Stock Analysis: A Biotech Innovator With 81.71% Potential Upside - DirectorsTalk Interviews
First Week of August 21st Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - MSN
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital - MSN
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8% - MarketBeat
Arcellx Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (ACLX) Movement - Stock Traders Daily
EPS Watch: Can Arcellx Inc stock reach 100 price target2025 Volume Leaders & Community Trade Idea Sharing Platform - moha.gov.vn
Wells starts Arcellx with overweight on multiple myeloma potential - MSN
Arcellx (NASDAQ:ACLX) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program - Yahoo Finance
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):